Valiant Laboratories Ltd
Incorporated in 1980, Valiant Laboratories
Ltd manufactures and deals in Pharmaceuticals and speciality chemicals[1]
- Market Cap ₹ 505 Cr.
- Current Price ₹ 93.0
- High / Low ₹ 133 / 69.8
- Stock P/E
- Book Value ₹ 43.2
- Dividend Yield 0.00 %
- ROCE -0.40 %
- ROE -0.93 %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- Company might be capitalizing the interest cost
- Company has high debtors of 197 days.
- Working capital days have increased from 127 days to 203 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| 334 | 182 | 133 | |
| 299 | 190 | 138 | |
| Operating Profit | 35 | -8 | -5 |
| OPM % | 11% | -5% | -4% |
| 5 | 10 | 5 | |
| Interest | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 |
| Profit before tax | 38 | -1 | -2 |
| Tax % | 24% | -142% | 46% |
| 29 | 0 | -2 | |
| EPS in Rs | 7.13 | 0.06 | -0.41 |
| Dividend Payout % | -0% | -0% | -0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -27% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 24% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -23% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | -1% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Equity Capital | 33 | 43 | 43 |
| Reserves | 68 | 193 | 191 |
| 60 | 77 | 122 | |
| 52 | 29 | 45 | |
| Total Liabilities | 213 | 343 | 401 |
| 48 | 50 | 48 | |
| CWIP | 1 | 43 | 156 |
| Investments | 34 | 38 | 4 |
| 130 | 212 | 193 | |
| Total Assets | 213 | 343 | 401 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| 56 | 2 | 1 | |
| -55 | -144 | -53 | |
| -1 | 152 | 45 | |
| Net Cash Flow | -0 | 10 | -7 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Debtor Days | 97 | 92 | 197 |
| Inventory Days | 17 | 22 | 12 |
| Days Payable | 62 | 56 | 127 |
| Cash Conversion Cycle | 52 | 57 | 82 |
| Working Capital Days | 71 | 109 | 203 |
| ROCE % | -2% | -0% |
Documents
Announcements
-
Submission Of Letter Of Offer For Rights Issue Of Fully Paid-Up Equity Shares Of Valiant Laboratories Limited
17 Jul - Valiant Labs files Letter of Offer for Rs. 81.47 Cr rights issue at Rs.75/share, 1:4 ratio, record date July 19, 2025.
-
Intimation Of ISIN For Right Entitlements For The Purpose Of Right Issue
16 Jul - ISIN INE0JWS20017 assigned for rights entitlements credit before issue opening date.
-
Rights Issue Of Equity Shares - Record Date July 19, 2025
15 Jul - Record date fixed as July 19, 2025 for Valiant Labs' Rights Issue entitlement credit.
- Corporate Action-Outcome of Right issue 15 Jul
-
Board Meeting Outcome for Approval Of Terms Of Rights Issue Of Equity Shares
15 Jul - Valiant Labs approves ₹81.47 Cr rights issue at ₹75/share, 1:4 ratio, opening July 28, 2025.
Business Overview:[1][2]
VLL is in the active pharmaceutical ingredient manufacturing business. It manufactures finished dosage forms of paracetamol API viz. Tablets, Capsules, and Other medications. Paracetamol API is a key ingredient used to treat a variety of conditions including Headache, Arthritis, Muscle Aches, Toothache, Backache, Cold, and Fever